A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have transformed cancer care but are frequently associated with immune-related adverse events (irAEs), complicating treatment. This retrospective cohort study analyzed 9193 adult patients from the OneFlorida+ Clinical Research Network who received ICIs between 2018 and 2022, aiming to identify risk factors for irAEs and evaluate their incidence, severity, and clinical impact. Among the 6,526 patients included in the final analysis, 56.2% developed irAEs within 1 year, including 284 hospitalized cases. Multivariable logistic regression revealed that younger age (18-29), female sex, and comorbidities such as myocardial infarction, heart failure, and renal disease increased irAE risk, while dementia and recent chemotherapy were associated with lower risk. P

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12606222 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature